Continued treatment for children with Hunter syndrome
Part of Brain & nervous system, Genetic & congenital, Hormones & metabolism, Skin clinical trials.
This program provides continued access to a treatment for children with Hunter syndrome after they finish a main study. It gives the study drug (idursulfase-IT) along with Elaprase to help manage symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You or your child must have finished the treatment phase of an earlier Hunter syndrome study (HGT-HIT-046 or SHP609-302).
- You or a parent/legal guardian must sign a consent form agreeing to take part in this compassionate access program.
- Your child must not have a known allergy to idursulfase-IT (the study drug) or its components.
- Your doctor must not think that participating would put your child at risk.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This is a follow-up study for people who already took JR-141 in an earlier trial for Hunter syndrome (MPS II). It checks how well the treatment works over the long term and monitors long-term safety.
This trial lets children who already took part in a previous CSL312 study for hereditary angioedema continue receiving the medicine. It helps ensure they don't have a gap in treatment while longer-term safety and effects are monitored.
This study tests a new enzyme replacement therapy called pegtibatinase for children with classical homocystinuria (HCU). The enzyme helps break down homocysteine, which may lower its levels in the blood and reduce symptoms.
This program lets people with von Willebrand disease who finished a previous study keep getting the treatment if it worked well and there's no other good option. It continues care after the study ends.
This study tests a new medicine called INM004 in children with STEC-HUS, a serious illness that damages the kidneys and blood cells. It may help speed up recovery and prevent complications.
This Phase 2 trial tests sotatercept, a medicine that targets the blood-vessel changes in pulmonary arterial hypertension (PAH), in children. It may help improve how well the heart and lungs work by changing the underlying disease process.
Hear when a new Hunter Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.